All In MedTech

FDA Clearance Tracker · P950021-S014

ADVIA CENTAUR PSA ASSAY

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jul 27, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jul 27, 2017

Approved

Time to decision

812 days

Received May 7, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P950021-S014
Device name
ADVIA CENTAUR PSA ASSAY
Applicant location
East Walpole, MA
Received
May 7, 2015
Decided
Jul 27, 2017
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P950021

Device type

Device class
Class III

Every decision under product code MTF

FDA's approval statement

As written in FDA's record.

Approval for the migration of the ADVIA Centaur PSA assay to the ADVIA Centaur XPT system

Source documents

Other decisions for Siemens Healthcare Diagnostics

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.